Compare · LMRI vs NTRA
LMRI vs NTRA
Side-by-side comparison of Lumexa Imaging Holdings Inc. (LMRI) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMRI and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $37.84B, about 37.0x LMRI ($1.02B).
- Over the past year, LMRI is down 42.4% and NTRA is up 91.9% - NTRA leads by 134.3 points.
- NTRA has been more active in the news (20 items in the past 4 weeks vs 1 for LMRI).
- NTRA has more recent analyst coverage (25 ratings vs 9 for LMRI).
- Company
- Lumexa Imaging Holdings Inc.
- Natera Inc.
- Price
- $10.66-4.05%
- $264.24-1.16%
- Market cap
- $1.02B
- $37.84B
- 1M return
- +12.21%
- +15.42%
- 1Y return
- -42.41%
- +91.85%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2015
- News (4w)
- 1
- 20
- Recent ratings
- 9
- 25
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest LMRI
- Lumexa Imaging Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Director Mittl Robert Louis Jr. was granted 19,358 shares (SEC Form 4)
- Director Lungren Matthew was granted 19,358 shares (SEC Form 4)
- Director Karlin Bridget E was granted 19,358 shares (SEC Form 4)
- Director Joseph Molly was granted 19,358 shares, increasing direct ownership by 72% to 46,385 units (SEC Form 4)
- Director Eisenberg Glenn A was granted 19,358 shares (SEC Form 4)
- Director Cooper Henry Lee was granted 19,358 shares (SEC Form 4)
- Director Brodnax Brett was granted 19,358 shares, increasing direct ownership by 31% to 81,385 units (SEC Form 4)
- SEC Form 8-K filed by Lumexa Imaging Holdings Inc.
- Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York
Latest NTRA
- Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
- Director Chapman Rowan E sold $37,101 worth of shares (135 units at $274.82) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 4,663 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $410,825 worth of shares (1,500 units at $273.88) as part of a pre-agreed trading plan (SEC Form 4)
- Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
- CO-FOUNDER Sheena Jonathan sold $836,898 worth of shares (3,150 units at $265.68) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 246,202 units (SEC Form 4)
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update